Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group..

Gynecol Oncol. 2006 Mar;100(3):537-43.

PMID:
16216315
2.

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group Study..

J Clin Oncol. 2005 Jul 20;23(21):4626-33.

PMID:
15911865
3.

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

Monk BJ, Huang HQ, Cella D, Long HJ 3rd; Gynecologic Oncology Group Study..

J Clin Oncol. 2005 Jul 20;23(21):4617-25. Erratum in: J Clin Oncol. 2005 Nov 20;23(33):8549.

PMID:
15911864
4.

Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.

Long HJ 3rd, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM Jr, Kardinal CG, Wos EJ.

Gynecol Oncol. 2006 Mar;100(3):501-5.

PMID:
16185755
5.
6.
8.

Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.

Long HJ 3rd, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP, Rayson S.

Gynecol Oncol. 1995 May;57(2):235-9.

PMID:
7729741
9.

[Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].

Ochi T, Ozawa A, Tanji N, Yanagihara Y, Yanagaki T, Miyauchi Y, Ikeda T, Shimamoto K, Toshino A, Sugawara T, Hamada H, Yokoyama M.

Nihon Hinyokika Gakkai Zasshi. 2006 Sep;97(6):777-81. Japanese.

10.

A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix.

Papadimitriou CA, Dimopoulos MA, Giannakoulis N, Sarris K, Vassilakopoulos G, Akrivos T, Voulgaris Z, Vlahos G, Diakomanolis E, Michalas S.

Cancer. 1997 Jun 15;79(12):2391-5.

PMID:
9191528
11.

Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.

Dowdy SC, Boardman CH, Wilson TO, Podratz KC, Hartmann LC, Long HJ.

Am J Obstet Gynecol. 2002 Jun;186(6):1167-73.

PMID:
12066092
12.
13.

Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.

Long HJ 3rd, Langdon RM Jr, Cha SS, Veeder MH, Pfeifle DM, Krook JE, Ebbert LP, Tschetter LK, Roshon SG.

Gynecol Oncol. 1995 Aug;58(2):240-3.

PMID:
7622111
14.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF.

J Clin Oncol. 2000 Sep;18(17):3068-77.

PMID:
11001674
15.

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.

Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.

Cancer. 2004 Apr 15;100(8):1639-45.

16.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.

Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029.

PMID:
18977518
17.

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S.

J Clin Oncol. 2004 Oct 1;22(19):3902-8.

PMID:
15459211
18.

Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.

Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Vlamis V, Higgins G, Herr H, Bajorin DF.

Cancer. 1999 Mar 1;85(5):1145-50.

PMID:
10091800
19.

[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].

Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M.

Urologe A. 2003 Aug;42(8):1074-86. German.

PMID:
14513232
20.

Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.

Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.

Eur Cytokine Netw. 1996 Sep;7(3):395-9.

PMID:
8954183
Items per page

Supplemental Content

Support Center